The Medulloblastoma Initiative (MBI) was established in 2021 to materialize the vision shared by Brazilian entrepreneur Fernando Goldsztein and Dr. Roger J. Packer, based at the Children's National Hospital in Washington DC.. The MBI raises private resources that are channeled to the research on Group 4 medulloblastoma developed by the Cure Group 4 Consortium — which includes 13 laboratories installed in the US, Canada, and Germany. Medulloblastoma is the most common pediatric brain cancer. Nevertheless, the treatment protocol used today has not changed since the 1980s.
In addition to not curing a large proportion of the children affected by medulloblastoma, current treatments impose severe, life-lasting side effects to the children who survive. And this is why the MBI works to connect private donors to great scientists.
Join us — "whoever saves one life saves the world entire".
Clinical trials just
around the corner
Dr. Duane Mitchell shares his thoughts
Dr. Duane Mitchell is a pioneer in the development of immunotherapies for patients with brain tumors. Mitchell brings to his work with the Cure Group 4 Consortium a fascination that began quite early with the potential to cure cancer using the patient's own cells — and the conviction that, within the next 5 years, we will have positive results for patients with recurrent Group 4 medulloblastoma.
"Children have an optimism that
they should never, never lose."
INTEGRATING THE CONSORTIUM
IN THE MEDIA
On Father's Day, journalist Cláudia Colucci and Folha de S.Paulo tell the story of MBI, which supports a consortium of laboratories seeking a cure for medulloblastoma — an initiative born from the experience of a father and a child facing this cancer.
Fernando Goldsztein's report on the MBI was published in the MIT Sloan School of Management newsletter.. Not by chance, MBI's story made it onto the list of the top 10 alumni stories in 2022.
The research supported the MBI to find a cure of medulloblastoma, the most common brain cancer in children, will soon begin clinical trials. For this new stage, in the coming months, MBI will seek $7 million in private donations.
"My son's illness changed my life,” says Fernando Goldsztein, MBI founder. He left an executive position at a large real estate company to support research aimed at finding a cure for medulloblastoma.
How did MBI start, and what difference can philanthropic donations make in advancing scientific research? "I never imagined the impact could be so significant," the founder of MBI told Brazil Journal.
In 2021, Brazilian journalist Daniel Scola was diagnosed with medulloblastoma. "I was among those saved thanks to science,,” he wrote when reporting about the MBI, "an innovative project that will greatly contribute to health globally".
In the US, the family of Leah, an 11-year old girl facing medulloblastoma, launched in 2023 a campaign to raise 50 thousand dollars for the research supported by the MBI. Lots of friends and relatives were ready to help, and the goal has already been met!
A platform for liquid biopsy — a simple blood test that will allow doctors to monitor the response of medulloblastoma to treatment, as well as detect tumor growth and signal early relapse — is one of the highlights of our research.